Actelion indicated that the Maestro study did not meet it primary endpoint, with results showing improvement for patients in exercise capacity, but with an even stronger improvement for placebo patients (!).
23 Jan 2017
The Maestro study did not meet its primary objective
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
The Maestro study did not meet its primary objective
Actelion indicated that the Maestro study did not meet it primary endpoint, with results showing improvement for patients in exercise capacity, but with an even stronger improvement for placebo patients (!).